Melanoma Posts on Medivizor
Navigation Menu

Melanoma Posts on Medivizor

High neutrophil-to-lymphocyte ratio in patients with melanoma treated with PD-1 inhibitor

Posted by on Dec 9, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out if a high neutrophil-to-lymphocyte ratio (NLR) was related to the survival of patients with melanoma treated with PD-1 inhibitor treatment. The study found that the higher the NLR, the lower the chances of survival in these patients.  Some background One type of melanoma treatment involves...

Read More

Evaluating the outcomes of patients with advanced melanoma with different treatments

Posted by on Dec 7, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out how well patients with advanced melanoma treated with certain medications survived outside of clinical trials. The study found that patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) or patients treated with anti-PD1 antibodies had longer survival compared to those treated with BRAF/MEK...

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

Evaluating long-term outcomes of nivolumab plus ipilimumab for patients with advanced melanoma

Posted by on Oct 20, 2019 in Melanoma | 0 comments

In a nutshell This study compared nivolumab (Opdivo) plus ipilimumab (Yervoy) to either drug alone for the treatment of advanced melanoma. The authors concluded that nivolumab plus ipilimumab or nivolumab alone increased survival compared to ipilimumab alone for these patients. Some background Advanced melanoma is a type of skin cancer that...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Melanoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More